Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC grew its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 337.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 346,723 shares of the company's stock after purchasing an additional 267,485 shares during the quarter. Voya Investment Management LLC owned approximately 0.14% of Maravai LifeSciences worth $1,890,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC raised its holdings in Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company's stock valued at $1,531,000 after buying an additional 143,184 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of Maravai LifeSciences in the third quarter worth $600,000. JPMorgan Chase & Co. increased its stake in Maravai LifeSciences by 1,172.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company's stock valued at $33,658,000 after purchasing an additional 3,731,924 shares in the last quarter. FNY Investment Advisers LLC lifted its position in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock valued at $38,000 after acquiring an additional 6,000 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Maravai LifeSciences by 7.3% in the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock worth $180,000 after purchasing an additional 2,239 shares during the last quarter. Institutional investors own 50.25% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRVI. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a research report on Friday, March 21st. Robert W. Baird cut Maravai LifeSciences from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. UBS Group lowered their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Morgan Stanley dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 25th. Finally, Baird R W downgraded shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $6.34.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock traded down $0.08 during mid-day trading on Tuesday, reaching $2.04. 1,523,189 shares of the company traded hands, compared to its average volume of 2,353,808. The firm's fifty day moving average is $2.23 and its two-hundred day moving average is $4.33. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a market capitalization of $518.85 million, a price-to-earnings ratio of -1.24 and a beta of 0.19.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.